Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.39 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.38 |
| ▸ | SYK | P43405 | 8/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.36 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.36 |
| ▸ | CCR2 | P41597 | 2/20 | 0.36 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
| ▸ | PPARD | Q03181 | 1/20 | 0.35 |
| ▸ | PPARA | Q07869 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3820292 | 0.81 | SYK (0.44) | FFAR4TRPV3SYKOPRM1OPRD1 | |
| SCHEMBL4150693 | 0.77 | OPRM1 (0.34) | OPRM1OPRD1OPRL1OPRK1CCR2 | |
| SCHEMBL4152521 | 0.73 | HDAC4 (0.39) | OPRM1OPRD1OPRL1OPRK1 | |
| SCHEMBL3386011 | 0.73 | KCNN4 (0.39) | OPRM1OPRD1OPRL1OPRK1 | |
| SCHEMBL18689716 | 0.73 | DRD2 (0.44) | OPRM1OPRD1OPRL1OPRK1 | |
| SCHEMBL3327490 | 0.73 | SYK (0.61) | TRPV3SYKOPRD1OPRK1HRH3 | |
| SCHEMBL3387388 | 0.71 | MC4R (0.40) | OPRM1OPRL1OPRK1 | |
| SCHEMBL17350664 | 0.71 | HSD11B1 (0.35) | OPRM1OPRD1OPRK1MAPT | |
| SCHEMBL22328947 | 0.70 | CCR2 (0.42) | FFAR4TRPV3SYKCCR2HRH3 | |
| SCHEMBL3772170 | 0.69 | OPRL1 (0.38) | OPRM1OPRD1OPRL1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8563582-B2 | 3-aminocyclopentanecarboxamides as modulators of chemokine receptors | INCYTE CORPORATION (US) | 2013-10-22 | — | — | US | disclosed |
| US-20090208485-A1 | 3-AMINOCYCLOPENTANECARBOXAMIDES AS MODULATORS OF CHEMOKINE RECEPTORS | INCYTE CORPORATION | 2009-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090208485-A1 | 3-AMINOCYCLOPENTANECARBOXAMIDES AS MODULATORS OF CHEMOKINE RECEPTORS | CCR5, ACKR3, CXCR3 | FFAR4 149/4885TRPV3 196/4885SYK 3720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.